Condition: Metastatic Breast Cancer · Recurrent Breast Cancer · Advanced Malignancies · Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
This is a phase Ib/II exploratory study. Phase Ib includes the dose escalation and expansion study of monotherapy, as well as the dose escalation study of combination therapy. After determining the maximum tolerated dose (MTD), a dose expansion study is conducted to observe the safety and efficacy in monotherapy. Phase II study is to further observe the safety and efficacy of TQB2930 combined with albumin-paclitaxel (cohort 3), or chemotherapy selected by investigators (cohort 4).
This description comes directly from the study's public registry record.
Qingyuan Zhang, Doctor · +86 0451 86298070 · sy86298276@163.com
Xiaohua Zeng, Doctor · 13983687701 · zengxiaohua000017@163.com
Always discuss trial participation with your own doctor first.
| Affiliated Cancer Hospital of Chongqing University | Chongqing, Chongqing Municipality, China | Recruiting |
| Affiliated cancer hospital of harbin medical university | Harbin, Heilongjiang, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06202261